Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E29.41 EPS (ttm)1.17 Insider Own0.04% Shs Outstand5.96B Perf Week-0.41%
Market Cap204.20B Forward P/E12.32 EPS next Y2.78 Insider Trans-7.90% Shs Float5.95B Perf Month2.08%
Income7.20B PEG4.63 EPS next Q0.67 Inst Own73.30% Short Float1.86% Perf Quarter5.45%
Sales52.83B P/S3.87 EPS this Y5.20% Inst Trans0.15% Short Ratio4.44 Perf Half Y2.06%
Book/sh9.80 P/B3.50 EPS next Y9.05% ROA4.20% Target Price38.00 Perf Year17.89%
Cash/sh3.00 P/C11.44 EPS next 5Y6.35% ROE11.60% 52W Range28.33 - 36.35 Perf YTD6.65%
Dividend1.28 P/FCF31.01 EPS past 5Y3.30% ROI7.80% 52W High-5.90% Beta0.97
Dividend %3.73% Quick Ratio1.00 Sales past 5Y-2.80% Gross Margin76.70% 52W Low20.70% ATR0.40
Employees96500 Current Ratio1.30 Sales Q/Q-3.00% Oper. Margin17.00% RSI (14)59.58 Volatility1.05% 1.10%
OptionableYes Debt/Eq0.71 EPS Q/Q600.90% Profit Margin13.70% Rel Volume0.58 Prev Close34.29
ShortableYes LT Debt/Eq0.53 EarningsJan 31 BMO Payout101.50% Avg Volume24.86M Price34.20
Recom2.50 SMA20-0.24% SMA503.62% SMA2003.25% Volume832,841 Change-0.26%
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Mar-24-17 06:46AM  Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment
05:50AM  Pfizer, Merck KGaA Get FDA Nod for Skin Cancer Drug (PFE) at Investopedia
03:40AM  Merck KgaA, Pfizer Cancer Drug to Cost $13,000 a Month
03:40AM  Merck KgaA, Pfizer Cancer Drug to Cost $13,000 a Month
Mar-23-17 05:56PM  US Market Indexes Lower With Losses Led by Energy Stocks
05:30PM  FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma PR Newswire
04:28PM  Pfizer, Merck KGaA's $13,000-a-Month Cancer Drug Wins Approval
03:10PM  FDA approves Pfizer, German Merck immunotherapy for skin cancer Reuters
09:47AM  Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse
08:33AM  Pfizers Lyrica Ineffective for Sciatica Pain (PFE) at Investopedia
Mar-22-17 02:47PM  Can Abbott Outperform Despite Alere?
10:30AM  Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts Business Wire
Mar-21-17 06:05PM  Japan May Prove to Be Strong Growth Driver for AstraZeneca in 2017
12:49PM  4 Health Care Charts Signaling Buys: Pfizer, Amgen Included
12:43PM  Investing Rookie? Start With These 3 Stocks at Motley Fool
12:13PM  7 Pharma Plays With Emerging Market Potential at
10:53AM  Nektar's Pain Drug Positive in Phase III Study; Shares Gain
10:00AM  Is Pfizer (PFE) a Great Stock for Value Investors?
07:30AM  [$$] SutroVax Set for Vaccine Trials After $64 Million Financing at The Wall Street Journal
07:00AM  Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks at Morningstar
Mar-20-17 09:56PM  [$$] White House Set to Announce Head of Senate Legislative Affairs Team at The Wall Street Journal
04:12PM  Anatomy Of A Decision, Part 1: The C-Suite
01:16PM  Eli Lilly Breast Cancer Combo Does Well In Trial at Investopedia
10:07AM  Lilly's breast cancer drug combination succeeds key study Reuters
09:41AM  Pfizer, Merck KGaA Delay Lung Cancer Drug Trial Outcome at Investopedia
Mar-19-17 07:22AM  3 Best Stocks for Your Roth IRA at Motley Fool
Mar-18-17 06:28PM  Cronos Group Execs Talk About Cannabis Co., Recent 'Bought Deal' And Expansion Plans
Mar-17-17 04:59PM  The Biggest Loser: Amgen Drops 6.4% at
04:03PM  Fired U.S. Attorney Preet Bharara Was Investigating HHS Chief Tom Price - Report
02:52PM  PFIZER INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
01:03PM  Amgen Blew ItFor Medicines Co., Esperion Too at
12:03PM  3 Best Pharmaceutical Stocks for Long-Term Investors at Motley Fool
11:15AM  Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation Business Wire
Mar-16-17 05:58PM  Final Trade: BAC, COH & more
05:00PM  How to trade deregulation: 6 stocks
04:40PM  Why PTC Therapeutics may have to lower the price on a $89,000-a-year drug it just bought at MarketWatch
10:49AM  Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China
08:02AM  Dividend Stocks Hedge Funds Are Betting On at Insider Monkey
Mar-15-17 09:00PM  Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ®, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis Business Wire
06:29PM  US Market Indexes Gain and Fed Raises Rate
05:46PM  Ex-Oppenheimer adviser gets six months in U.S. insider trading case
03:41PM  Will Pfizer's Growth Be Threatened by Novartis' New Cancer Drug? at Motley Fool
02:13PM  Pfizers Cash Flow Stamina versus Mercks Ambitious R&D
12:40PM  Bernie Sanders Slams Sanofi Zika Vaccine Deal at Investopedia
11:07AM  3 Safe Stocks to Invest In for an Aging Bull Market at Motley Fool
10:37AM  David Tepper on Allergan: Does It Look Cheap?
08:09AM  Turning Pfizer Discards Into Novartis Gold: The Story Of Ziarco at Forbes
Mar-14-17 05:49PM  Unilever CEO urges UK to provide 'level playing field' after Kraft bid Reuters
05:41PM  Novartis Takes Aim at Pfizer in Breast Cancer at Motley Fool
04:14PM  Novartis Breast Cancer Drug Just OK'd And Already Losing?
03:43PM  AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results
03:05PM  Pfizer Unveils Zavicefta Antibiotic in Germany, UK at Investopedia
10:13AM  Novartis wins U.S. approval for breast cancer drug; to compete with Pfizer's Ibrance Reuters
08:31AM  [$$] Don't Expect Pfizer to Make a Mega Acquisition at
07:36AM  Johnson & Johnsons Pharmaceuticals Segment
05:00AM  Pfizer Launches Zavicefta (ceftazidime-avibactam) in the U.K. and Germany, a New Antibiotic to Treat Complicated Infections Caused by Gram-Negative Bacteria Business Wire
Mar-13-17 04:23PM  Better Buy: Eli Lilly and Company vs. Pfizer at Motley Fool
03:45PM  Intrexon executive out less than a year after joining the company at
11:18AM  Billionaire David Tepper Makes Huge Investments In These 4 Drug Stocks at Insider Monkey
10:37AM  Johnson & Johnsons Business Segment Performance
10:30AM  Pfizer Inc. :PFE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 13, 2017
08:41AM  The 19 Best-Selling Prescription Drugs of All-Time at Motley Fool
07:37AM  Johnson & Johnsons Valuation Compared to Its Peers
Mar-12-17 03:40PM  The 10 Most Important Tips for Playing the Stock Market in March
11:41AM  3 Big Pharma Stocks To Buy in Your 401(k) at Motley Fool
08:42AM  The 3 Most Important Numbers for Johnson & Johnson at Motley Fool
Mar-11-17 12:04PM  Better Buy: Myriad Genetics, Inc. vs. Opko Health, Inc. at Motley Fool
Mar-10-17 12:36PM  Jobs report beats expectations
08:00AM  Biogen Spinoff Takes Flight With Focus On Hemophilia Drugs
06:10AM  The 6 Most Shorted NYSE Stocks
Mar-09-17 04:03PM  Will Pfizer Take On Celgene, Other Rivals With Leukemia Drug?
09:30AM  The Zacks Analyst Blog Highlights: Caterpillar, Apple and Pfizer
08:59AM  Pharma says high prices fund drug development but this study finds otherwise at MarketWatch
Mar-08-17 05:39PM  Global Blood Therapeutics Shares Jump on Report It Was Approached by Novo Nordisk
04:23PM  1 Thing About Pfizer, Inc. Stock That You Might Be Overlooking at Motley Fool
04:22PM  This Pharma Firm Is Beating The Pack In Getting Drugs To Market
01:43PM  Caterpillar Stock Slides After Report Accuses It of Tax Fraud
11:01AM  Pfizer Inc. (PFE) Reportedly In Talks To Expand Plant In Lee County at Insider Monkey
10:30AM  Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA
10:00AM  Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire
09:30AM  J2 Global, eHealth, Pfizer, Amgen and Mylan highlighted as Zacks Bull and Bear of the Day
08:35AM  State Street Calls for More Women on Boards
08:04AM  Forget the Distractions: Bristol-Myers Squibb Is a Bargain at Motley Fool
07:25AM  Are Hedge Funds Turning Bearish on Healthcare Stocks? at Insider Monkey
06:58AM  US Indexes Lower on Energy Stock Losses
05:37AM  FDA Endorses 3 New Drug Applications (NDAs) From Merck & Co., Inc. (MRK), Pfizer Inc. (PFE) at Insider Monkey
Mar-07-17 08:25PM  Trump's Twitter tantrums a pharma buying opportunity
06:41PM  Cramer: Why Trumps Twitter tantrums on pharma are your b...
05:20PM  Drugmakers fall as investors see pricing threat from Trump
04:55PM  Stocks today: Dow, S&P 500 slip as rally pauses on Obamacare repeal; Trump talks tax cuts right before closing bell at
04:05PM  Stocks Fall for Day Two as Trump Targets Health Care Sector
04:01PM  Chevron, Verizon Sink DJIA on Tuesday
03:50PM  Trump's Tweet Hits Pharma Stocks, Promises Decreased Drug Prices
03:30PM  Sources: Pfizer considering $100M plant expansion in the Triangle at
01:30PM  Trump's Tax Plans: Biggest Winners and Losers
11:37AM  Stock market fights for altitude, but health-care, energy slide weigh at MarketWatch
10:36AM  Ten stocks to watch with focus on Obamacare, drug prices; Dow Jones dips; Snap slides 10 percent early at
10:03AM  Trump Tweets, Drug Stocks Tank
09:48AM  Trump's Latest Drug Pricing Tweet Hits Biotech Stocks at The Wall Street Journal
09:21AM  Is Portola Pharmaceuticals Balance Sheet Safe? at Motley Fool
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Viagra, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that will lose or have lost marketing patent protection; branded generic products; sterile injectable products; biosimilars; and infusion systems. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, and Pristiq brand names. This segment also engages in contract manufacturing business. The company has licensing agreements with Cellectis SA and AstraZeneca plc; and collaborative agreements with Eli Lilly & Company and Merck KGaA. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JOHNSON RADY AExecutive Vice PresidentMar 10Sale34.194,500153,85554,963Mar 13 05:36 PM
HILL CHARLES HExecutive Vice PresidentMar 09Sale34.0736,0001,226,52057,329Mar 10 03:59 PM
Dolsten MikaelPresident R&DMar 02Sale34.5515,401532,10549,318Mar 03 04:06 PM
LANKLER DOUGLAS MExecutive Vice PresidentMar 02Sale34.6620,000693,20083,793Mar 03 04:06 PM
Dolsten MikaelPresident R&DMar 01Sale34.4815,569536,81964,719Mar 03 04:06 PM
Dolsten MikaelPresident R&DFeb 27Sale34.2658,8462,016,24480,288Mar 01 05:10 PM
JOHNSON RADY AExecutive Vice PresidentFeb 23Option Exercise21.0321,238446,63572,172Feb 27 06:30 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 23Option Exercise21.03103,1552,169,350295,356Feb 27 06:30 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 23Option Exercise21.0351,5781,084,685138,758Feb 27 06:30 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 23Option Exercise21.0321,238446,63533,848Feb 27 06:30 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 23Option Exercise21.03218,4474,593,940592,765Feb 27 06:21 PM
BOURLA ALBERTGroup PresidentFeb 23Option Exercise21.0342,476893,270165,474Feb 27 06:21 PM
Dolsten MikaelPresident R&DFeb 23Option Exercise21.03218,4474,593,940299,915Feb 27 06:21 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 23Option Exercise21.0336,408765,660102,611Feb 27 06:10 PM
READ IAN CChairman & CEOFeb 23Option Exercise21.03788,83516,589,2001,124,093Feb 27 06:55 PM
SUSMAN SALLYExecutive Vice PresidentFeb 23Option Exercise21.03115,2912,424,570247,765Feb 27 06:55 PM
YOUNG JOHN DGroup PresidentFeb 23Option Exercise21.0351,5781,084,685172,542Feb 27 06:56 PM
OLSON LAURIE JExecutive Vice PresidentFeb 23Option Exercise21.0327,306574,24599,224Feb 27 06:47 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 07Option Exercise25.8730,000776,100167,687Dec 08 09:48 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 09Sale33.0010,000330,000112,087Nov 10 07:44 PM
BOURLA ALBERTGroup PresidentNov 04Option Exercise24.9920,000499,800149,199Nov 07 05:58 PM
BOURLA ALBERTGroup PresidentNov 04Sale30.0518,390552,530130,809Nov 07 05:58 PM
HILL CHARLES HExecutive Vice PresidentNov 03Option Exercise21.0353,9181,133,896115,033Nov 07 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 02Option Exercise21.0332,545684,421122,087Nov 04 04:36 PM
DAMELIO FRANK AExecutive Vice PresidentMay 26Option Exercise24.43100,0002,443,000472,994May 27 11:03 AM
DAMELIO FRANK AExecutive Vice PresidentMay 26Sale34.49100,0003,449,115372,994May 27 11:03 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Option Exercise25.8786,0002,224,820271,663May 26 10:07 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Sale33.9786,0002,921,147185,663May 26 10:07 AM
YOUNG JOHN DGroup PresidentMay 10Option Exercise25.8741,7001,078,779200,399May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Option Exercise24.43192,0004,690,560564,994May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Sale33.66192,0006,462,579372,994May 11 06:04 PM
YOUNG JOHN DGroup PresidentMay 10Sale33.5341,7001,398,277158,699May 11 06:04 PM
READ IAN CChairman & CEOMay 09Option Exercise25.74275,0007,078,2501,471,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Option Exercise22.2823,884532,136199,735May 11 04:35 PM
HILL CHARLES HExecutive Vice PresidentMay 09Sale33.8429,6001,001,65160,828May 11 04:35 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Sale33.7167,8842,288,669131,851May 11 04:35 PM
READ IAN CChairman & CEOMay 09Sale33.80275,0009,295,0391,196,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 05Option Exercise22.2856,0161,248,036231,867May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 05Sale33.7156,0161,888,144175,851May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Option Exercise22.2820,100447,828195,951May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Sale33.8720,100680,762175,851May 06 09:51 AM
DAMELIO FRANK AExecutive Vice PresidentMay 03Sale33.6587,0792,930,208372,994May 05 05:27 PM